Analyzing Elekta (OTCMKTS:EKTAY) and Venus Concept (NASDAQ:VERO)

Elekta (OTCMKTS:EKTAY) and Venus Concept (NASDAQ:VERO) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, dividends, earnings and risk.

Insider and Institutional Ownership

87.4% of Venus Concept shares are held by institutional investors. 41.3% of Elekta shares are held by company insiders. Comparatively, 28.0% of Venus Concept shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Volatility & Risk

Elekta has a beta of 1, indicating that its share price has a similar volatility profile to the S&P 500.Comparatively, Venus Concept has a beta of -0.06, indicating that its share price is 106% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations and price targets for Elekta and Venus Concept, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elekta	2	0	0	0	1.00
Venus Concept	1	0	0	0	1.00

Valuation and Earnings

This table compares Elekta and Venus Concept”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elekta	$1.78 billion	1.19	-$55.30 million	($0.16)	-35.81
Venus Concept	$58.88 million	0.01	-$47.00 million	($48.84)	-0.01

Venus Concept has lower revenue, but higher earnings than Elekta. Elekta is trading at a lower price-to-earnings ratio than Venus Concept, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Elekta and Venus Concept’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Elekta	-3.32%	10.67%	3.21%
Venus Concept	-92.76%	-1,904.25%	-85.22%

Summary

Elekta beats Venus Concept on 8 of the 11 factors compared between the two stocks.

About Elekta

Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders worldwide. The company offers Versa HD, a brain metastases solution; Elekta Unity for real-time MR visualization; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; Elekta Synergy, a digital accelerator for image guided radiation therapy; treatment and workflow management solutions; radiation and medical oncology; and other patient services. It also provides Elekta Studio, an image guided brachytherapy solution; ImagingRing, a mobile CT scanner; Oncentra Brachy, a smart tool that facilitate repetitive tasks; Venezia applicator that enables the oncologist to treat locally advanced cervical cancer; Elekta Flexitron afterloader for enabling the precise execution of all steps in the workflow; Geneva, an applicator for cervical cancer treatment; veterinary radiation therapy products; and Elekta Kaiku for personalized cancer care. In addition, the company offers stereotactic radiosurgery, such as Leksell Gamma Knife Icon for personalized radiation treatment; Leksell Gamma Knife Perfexion, a tool for radiosurgeons; and Elekta Esprit. Further, it provides neurosurgery products comprising Leksell Vantage Stereotactic System for intracranial neurosurgery; and Leksell Stereotactic System for minimally invasive stereotactic neurosurgery. The company was incorporated in 1972 and is headquartered in Stockholm, Sweden.

About Venus Concept

Venus Concept Inc., a medical technology company, develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies, and related services in the United States and internationally. Its product portfolio includes Venus Legacy, a noninvasive device used in dermatological and general surgical procedures for females; Venus Versa, a multi-application device used in aesthetic and cosmetic procedures; Venus Versa Pro; and Venus Viva and Venus Viva MD, an advanced, portable, and fractional RF system for dermatological procedures requiring ablation and resurfacing of the skin. The company also offers Venus Fiore, a device that delivers non-thermal RF with massage and magnetic field pulses to treat various medical conditions; Venus Bliss and Venus Bliss Max for non-invasive lipolysis of the abdomen, back, thights, and flanks in individuals with a body mass index of 30 or less; Venus Glow, a dermabrasion device used to improve skin appearance; and NeoGraft, an advanced hair restoration technology with an automated FUE and implantation system. In addition, it provides Venus Velocity and Venus Epileve for hair removal, permanent hair reduction, and treatment of pseudofolliculitis barbae; ARTAS iX, a robotic system to assist physicians in identifying and extracting hair follicles units from the scalp during hair transplantation, creating recipient sites, and implanting the harvested hair follicles; and AI.ME an interactive, image-guided, and computer assisted system for fractional skin resurfacing. The company is headquartered in Toronto, Canada.